Log in to save to my catalogue

Real-world data on the efficacy and safety of daratumumab treatment in Hungarian relapsed/refractory...

Real-world data on the efficacy and safety of daratumumab treatment in Hungarian relapsed/refractory...

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_miscellaneous_2270019042

Real-world data on the efficacy and safety of daratumumab treatment in Hungarian relapsed/refractory multiple myeloma patients

About this item

Full title

Real-world data on the efficacy and safety of daratumumab treatment in Hungarian relapsed/refractory multiple myeloma patients

Publisher

Tokyo: Springer Japan

Journal title

International journal of hematology, 2019-11, Vol.110 (5), p.559-565

Language

English

Formats

Publication information

Publisher

Tokyo: Springer Japan

More information

Scope and Contents

Contents

Daratumumab is a human anti-CD38 monoclonal antibody used in the treatment of refractory and relapsed multiple myeloma. We investigated the efficacy and safety of daratumumab therapy in a real-world setting. Ninety-nine Hungarian patients were included; 48 received monotherapy, while lenalidomide and bortezomib combinations were administered in 29...

Alternative Titles

Full title

Real-world data on the efficacy and safety of daratumumab treatment in Hungarian relapsed/refractory multiple myeloma patients

Identifiers

Primary Identifiers

Record Identifier

TN_cdi_proquest_miscellaneous_2270019042

Permalink

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_miscellaneous_2270019042

Other Identifiers

ISSN

0925-5710

E-ISSN

1865-3774

DOI

10.1007/s12185-019-02715-w

How to access this item